Nanomedicine-boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma  

作　　者：Yi Lu Yue Gao Huan Yang Yong Hu Xin Li 

机构地区：[1]Department of Polymeric Materials,School of Materials Science and Engineering,Tongji University,Shanghai 201804,China [2]Institute of Biotechnology,RWTH Aachen University,52074 Aachen,Germany [3]DWI-Leibniz-Institute for Interactive Materials e.V.,52056 Aachen,Germany [4]College of Chemistry,Chemical Engineering and Biotechnology,Donghua University,Shanghai 201620,China [5]School of Pharmacy,Jiangsu University,Zhenjiang 212013,Jiangsu,China [6]Institute of Technical and Macromolecular Chemistry,RWTH Aachen University,52074 Aachen,Germany

出　　处：《Military Medical Research》2023年第3期403-414,共12页军事医学研究（英文版）

基　　金：supported by the National Natural Science Foundation of China(52103181,81873196);the Sino-German Center for Research Promotion(GZ1505);the Fundamental Research Funds for the Central Universities(22120220075);the China Scholarship Council(201908320330)。

摘　　要：Traditional treatments for advanced hepatocellular carcinoma(HCC),such as surgical resection,transplantation,radiofrequency ablation,and chemotherapy are unsatisfactory,and therefore the exploration of powerful therapeutic strategies is urgently needed.Immunotherapy has emerged as a promising strategy for advanced HCC treatment due to its minimal side effects and long-lasting therapeutic memory effects.Recent studies have demonstrated that icaritin could serve as an immunomodulator for effective immunotherapy of advanced HCC.Encouragingly,in 2022,icaritin soft capsules were approved by the National Medical Products Administration(NMPA)of China for the immunotherapy of advanced HCC.However,the therapeutic efficacy of icaritin in clinical practice is impaired by its poor bioavailability and unfavorable in vivo delivery efficiency.Recently,functionalized drug delivery systems including stimuli-responsive nanocarriers,cell membrane-coated nanocarriers,and living cell-nanocarrier systems have been designed to overcome the shortcomings of drugs,including the low bioavailability and limited delivery efficiency as well as side effects.Taken together,the development of icaritin-based nanomedicines is expected to further improve the immunotherapy of advanced HCC.Herein,we compared the different preparation methods for icaritin,interpreted the HCC immune microenvironment and the mechanisms underlying icaritin for treatment of advanced HCC,and discussed both the design of icaritin-based nanomedicines with high icaritin loading and the latest progress in icaritinbased nanomedicines for advanced HCC immunotherapy.Finally,the prospects to promote further clinical translation of icaritin-based nanomedicines for the immunotherapy of advanced HCC were proposed.

关 键 词：ICARITIN NANOMEDICINE Advanced hepatocellular carcinoma IMMUNOTHERAPY Clinical translation 

分 类 号：TB383.1[一般工业技术—材料科学与工程] R735.7[医药卫生—肿瘤]